The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
Eva Agnes Odongpiny LakerArnold ArinaitweNoela OwarwoAnnet OnziaBenson NasasiraAbdullah WailagalaIvan KaluleGodwin AnguzuAgnes KiraggaKay SedenIsaac LwangaBarbara CastelnuovoRachel MusombaMohammed LamordePublished in: Drug safety (2021)
A rapid well-coordinated response ensured prompt communication of the dolutegravir safety warning. The process developed by the clinic can act as a model for response during drug safety alerts. Women made informed decisions with most opting to remain taking dolutegravir; however, effective contraception uptake was low.
Keyphrases
- antiretroviral therapy
- polycystic ovary syndrome
- hiv infected patients
- pregnancy outcomes
- hiv infected
- primary care
- human immunodeficiency virus
- breast cancer risk
- hiv positive
- cervical cancer screening
- hepatitis c virus
- adipose tissue
- hiv aids
- metabolic syndrome
- emergency department
- climate change
- hiv testing
- pregnant women
- drug induced